Gastrointestinal Involvement

Overview

• Raynaud's Overview

Articles

• "Pathogenesis of Vascular Disease in Scleroderma," by Richard M. Silver, M.D., originally published on "Medscape Today" (January 2007)
• "Questions and Answers about Raynaud's Phenomenon." This is an NIH Publication, No. 06-4911. Publication Date: May 2001, revised: June 2006
• "Bosentan Inhibits Digital Ulcers in Scleroderma," by Nancy Walsh, (New York Bureau), "Rheumatology News," Volume 5, Issue 1, Page 14 (January 2006)
• Raynaud Phenomenon, by Alice Reilly MSN, RN, APN, C, COHN-S & Barbara Snyder PhD, APRN, BC
  AJN, "American Journal of Nursing"
  This article describes the difference between primary and secondary Raynaud phenomenon and reviews etiology, diagnosis, prevention, and management of symptoms.
  AJN, "American Journal of Nursing"

  © 2005 Lippincott Williams & Wilkins, Inc. Volume 105(8), August 2005, pp 56-65

• Bosentan (Tracleer®) Showed Statistically Significant Reduction of New Digital Ulcerations in Scleroderma Patients, based on “Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist” by J. H. Korn et al., published in "Arthritis and Rheumatism," Volume 50, Issue 12, pages 3985-3993.
• "Raynaud's Phenomenon and Scleroderma," by Richard Silver, M.D., Professor of Medicine, Medical University of South Carolina (originally published in Scleroderma Voice, 2002 Issue #1)
• Raynaud's Phenomenon and Ulcerations (Question and Answer), by Philip Clements, M.D., UCLA School of Medicine, Department of Rheumatology, (originally published in Scleroderma Voice, Spring 2001)